• A case of erythrogenic protoporphyria with thyrotoxicosis and liver dysfunction in an adult female
• A gel-forming α-MSH analog promotes lasting melanogenesis
• A Mysterious Abdominal Pain
• A Severe Reaction After Phototherapy in a Neonate With X-Linked Protoporphyria
• Absorption, metabolism, and excretion of [¹⁴ C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers
• Activation of the NLRP3 inflammasome by HMGB1 through inhibition of the Nrf2/HO-1 pathway promotes bleomycin-induced pulmonary fibrosis after acute lung injury in rats
• Afamelanotide
• Afamelanotide for Treatment of the Protoporphyrias: Impact on Quality of Life and Laboratory Parameters in a US Cohort
• Afamelanotide in protoporphyria and other skin diseases: a review
• Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria
• An adaptor for feedback regulation of heme biosynthesis by the mitochondrial protease CLPXP
• An overview of benefits and risks of chronic melanocortin-1 receptor activation
• An overview of porphyrias
• Case report: Xeroderma pigmentosum Group A with erythropoietic protoporphyria in a young Chinese patient
• Cimetidine Does Not Inhibit 5-Aminolevulinic Acid Synthase or Heme Oxygenase Activity: Implications for Treatment of Acute Intermittent Porphyria and Erythropoietic Protoporphyria
• Comment on "Liver involvement in patients with erythropoietic protoporphyria"
• Consecutive Liver and Bone Marrow Transplantation for Erythropoietic Protoporphyria: Case Report and Literature Review
• Current trials in erythropoietic protoporphyria: are placebo controls ethical?
• Definitive Confirmation of Erythropoietic Protoporphyria via Re-biopsy Three Years After Initial Liver Biopsy at Age 15
• Dersimelagon in Erythropoietic Protoporphyrias
• Dersimelagon in Erythropoietic Protoporphyrias. Reply
• Development and content validation of a sunlight exposure diary in patients with erythropoietic protoporphyria
• Development and Content Validation of Novel Patient-Reported Outcome Measures to Assess Disease Severity and Change in Patients with Erythropoietic Protoporphyria: The EPP Impact Questionnaire (EPIQ)
• Diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and x-linked protoporphyria: A patient-friendly summary of the 2023 evidence-based consensus guidelines
• Edaravone dexborneol protects against cerebral ischemia/reperfusion-induced blood-brain barrier damage by inhibiting ferroptosis via activation of nrf-2/HO-1/GPX4 signaling
• Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT-7117), an Oral Melanocortin-1 Receptor Agonist
• Effects of iron supplements in individuals with erythropoietic protoporphyria
• Elucidating the Role of Human ALAS2 C-terminal Mutations Resulting in Loss of Function and Disease
• Erythropoietic protoporphyria and afamelanotide: a patient's perspective
• Erythropoietic protoporphyria: case reports for clinical and therapeutic hints
• Erythropoietic protoporphyrias: Pathogenesis, diagnosis and management
• Erythropoietic protoporphyrias: updates and advances
• Evaluation of living donors for hereditary liver disease (siblings, heterozygotes)
• Evidence based consensus guidelines for diagnosis and management of Protoporphyria-Related liver dysfunction in erythropoietic protoporphyria and X-Linked protoporphyria
• Evidence-based consensus guidelines for the diagnosis and management of protoporphyria-related liver dysfunction in erythropoietic protoporphyria and X-linked protoporphyria
• Fair Funding Decisions: Consistency of the Time Horizons Used in the Calculation of Quality-Adjusted Life Years for Therapies for Very Rare Diseases by the National Institute for Health and Care Excellence in England
• Heme oxygenase-1 is an equid alphaherpesvirus 8 replication restriction host protein and suppresses viral replication via the PKCβ/ERK1/ERK2 and NO/cGMP/PKG pathway
• Hepatic farnesoid X receptor is necessary to facilitate ductular reaction and expression of heme biosynthetic genes
• Illuminating Dersimelagon: A Novel Agent in the Treatment of Erythropoietic Protoporphyria and X-Linked Protoporphyria
• Into the Light: Afamelanotide and the Treatment of Erythropoietic Protoporphyria in the United States
• Letter to the Editor: Contrasting effect of iron supplementation in protoporphyria
• Liver transplantation and primary liver cancer in porphyria
• Living-Donor Liver Transplantation for Erythropoietic Protoporphyria: A Case Report and Literature Review
• Management of erythropoietic protoporphyria with cholestatic liver disease: A case report
• Murine models of erythroid 5ALA synthesis disorders and their conditional synthetic lethal dependency on pyridoxine
• NOVEL THERAPEUTIC APPROACHES IN THALASSEMIAS, SICKLE CELL DISEASE AND OTHER RED CELL DISORDERS
• Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders
• Observational pilot study of multi-wavelength wearable light dosimetry for erythropoietic protoporphyria
• Peptide Conjugates of a 2'-<em>O</em>-Methoxyethyl Phosphorothioate Splice-Switching Oligonucleotide Show Increased Entrapment in Endosomes
• Photosensitivity
• Photosensitivity
• Porphyrias: Uncommon disorders masquerading as common childhood diseases
• Protoporphyrin IX-induced phototoxicity: Mechanisms and therapeutics
• Quality of life in children with erythropoietic protoporphyria: a case-control study
• Reply: Contrasting effect of iron supplementation in protoporphyria
• Successful treatment of severe hepatic impairment in erythropoietic protoporphyria: A case report and review of literature
• Targeting the central melanocortin system for the treatment of metabolic disorders
• The effects of cholecalciferol and afamelanotide on vitamin D levels in erythropoietic protoporphyria; a multicentre cohort study
• The role of allogeneic stem cell transplantation in severe erythropoietic protoporphyria in adults and young adults: timing and modalities
• Update on the Porphyrias
• When the diagnosis is written in the DNA: a case of erythropoietic protoporphyria in a patient with a chromosome-18 deletion
• X-linked Dominant Erythropoietic Protoporphyria with early-onset manifestations caused by a hemizygous ALAS2 variant